{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:54:40Z","timestamp":1782741280836,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.nbd.2024.106459","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T17:21:19Z","timestamp":1709054479000},"page":"106459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The free plasma amyloid A\u03b21\u201342\/A\u03b21\u201340 ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma A\u03b21\u201342\/A\u03b21\u201340 ratio. The BALTAZAR study"],"prefix":"10.1016","volume":"193","author":[{"given":"S.","family":"Schraen-Maschke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Duhamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ramdane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vaudran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dussart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bu\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sablonni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Delaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Allinquant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bombois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2006.09.002","article-title":"Conversion from cognitive health to mild cognitive impairment and Alzheimer\u2019s disease: prediction by plasma amyloid Beta 42, medial temporal lobe atrophy and homocysteine","volume":"29","author":"Blasko","year":"2008","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.nbd.2024.106459_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JAD-2009-1144","article-title":"Amyloid-\u03b242 plasma levels are elevated in amnestic mild cognitive impairment","volume":"18","author":"Cammarata","year":"2009","journal-title":"\u00c9dit\u00e9 Garth Bissette. J. Alzheimer\u2019s Disease"},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","article-title":"Plasma amyloid-\u03b2 and risk of Alzheimer\u2019s disease in the Framingham heart study","volume":"11","author":"Chouraki","year":"2015","journal-title":"Alzheimers Dement."},{"issue":"15","key":"10.1016\/j.nbd.2024.106459_bb0020","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","article-title":"Total A\u03b2 42 \/A\u03b2 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis","volume":"94","author":"Doecke","year":"2020","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.nbd.2024.106459_bb0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2011.03.005","article-title":"The relationship of plasma A\u03b2 levels to dementia in aging individuals with mild cognitive impairment","volume":"305","author":"Fei","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3233\/JAD-191227","article-title":"The amyloid, tau, and neurodegeneration (a\/T\/N) classification applied to a clinical research cohort with long-term follow-up","volume":"74","author":"Gr\u00f8ntvedt","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.nbd.2024.106459_bb0035","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer\u2019s process and correlations with central biomarkers","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"12","key":"10.1016\/j.nbd.2024.106459_bb0040","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/alz.12613","article-title":"Plasma amyloid Beta predicts conversion to dementia in subjects with mild cognitive impairment: the BALTAZAR study","volume":"18","author":"Hanon","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neurobiolaging.2008.03.027","article-title":"Evaluation of plasma A\u03b240 and A\u03b242 as predictors of conversion to Alzheimer\u2019s disease in patients with mild cognitive impairment","volume":"31","author":"Hansson","year":"2010","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.nbd.2024.106459_bb0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/acn3.160","article-title":"CSF Beta-amyloid 1-42 - what are we measuring in Alzheimer\u2019s disease?","volume":"2","author":"Hu","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.nbd.2024.106459_bib236","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0055","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2024.106459_bb0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mex.2015.02.011","article-title":"Signal loss due to oligomerization in ELISA analysis of amyloid-Beta can be recovered by a novel sample pre-treatment method","volume":"2","author":"Janssen","year":"2015","journal-title":"MethodsX"},{"issue":"7","key":"10.1016\/j.nbd.2024.106459_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2011.1841","article-title":"Plasma amyloid-\u03b2 as a predictor of dementia and cognitive decline: a systematic review and meta-analysis","volume":"69","author":"Koyama","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3233\/JAD-200900","article-title":"Blood-based ATN biomarkers of Alzheimer\u2019s disease: a meta-analysis","volume":"79","author":"Koychev","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0075","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1006\/bbrc.1999.0552","article-title":"High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer\u2019s disease","volume":"257","author":"Kuo","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.nbd.2024.106459_bb0080","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3233\/JAD-2012-121075","article-title":"Validation of a multiplex assay for simultaneous quantification of amyloid-\u03b2 peptide species in human plasma with utility for measurements in studies of Alzheimer\u2019s disease therapeutics","volume":"32","author":"Lachno","year":"2012","journal-title":"J. Alzheimer\u2019s Disease: JAD"},{"issue":"11","key":"10.1016\/j.nbd.2024.106459_bb0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1212\/WNL.0b013e3181b78448","article-title":"Association of Plasma Amyloid with risk of dementia: the prospective Three-City study","volume":"73","author":"Lambert","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/alzrt267","article-title":"A diagnostic scale for Alzheimer\u2019s disease based on cerebrospinal fluid biomarker profiles","volume":"6","author":"Lehmann","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0095","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"19","key":"10.1016\/j.nbd.2024.106459_bb0100","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1212\/01.wnl.0000306696.82017.66","article-title":"Plasma amyloid levels and the risk of AD in Normal subjects in the cardiovascular health study","volume":"70","author":"Lopez","year":"2008","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.nbd.2024.106459_bb0105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jalz.2019.04.008","article-title":"Blood amyloid levels and risk of dementia in the Ginkgo evaluation of memory study (GEMS): a longitudinal analysis","volume":"15","author":"Lopez","year":"2019","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.nbd.2024.106459_bb0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jalz.2016.12.004","article-title":"Plasma concentrations of free amyloid \u03b2 cannot predict the development of Alzheimer\u2019s disease","volume":"13","author":"L\u00f6vheim","year":"2017","journal-title":"Alzheimers Dement."},{"issue":"juillet","key":"10.1016\/j.nbd.2024.106459_bb0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fnagi.2017.00226","article-title":"Plasma levels of A\u03b242 and Tau identified probable Alzheimer\u2019s dementia: findings in two cohorts","volume":"9","author":"Lue","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.nbd.2024.106459_bb0125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","article-title":"Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies","volume":"119","author":"Mitchell","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"7691","key":"10.1016\/j.nbd.2024.106459_bb0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.nbd.2024.106459_bb0135","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1093\/brain\/awac297","article-title":"Amyloid-\u03b2 levels and cognitive trajectories in non-demented PTau181-positive subjects without Amyloidopathy","volume":"145","author":"Oberstein","year":"2022","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.nbd.2024.106459_bb0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","article-title":"Plasma A\u03b21\u201340 and A\u03b21\u201342 and the risk of dementia: a prospective case-cohort study","volume":"5","author":"van Oijen","year":"2006","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12021-016-9295-8","article-title":"CATI: a large distributed infrastructure for the neuroimaging of cohorts","volume":"14","author":"Operto","year":"2016","journal-title":"Neuroinformatics"},{"issue":"8","key":"10.1016\/j.nbd.2024.106459_bb0150","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement."},{"issue":"12","key":"10.1016\/j.nbd.2024.106459_bb0155","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.nbd.2024.106459_bb0160","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer Disease\u2013Related \u03b2-Amyloid Status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0165","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-121744","article-title":"Several direct and calculated biomarkers from the amyloid-\u03b2 Pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment","volume":"36","author":"P\u00e9rez-Grijalba","year":"2013","journal-title":"J. Alzheimer\u2019s Disease: JAD"},{"key":"10.1016\/j.nbd.2024.106459_bb0170","article-title":"Reliable measurements of the \u03b2-amyloid Pool in blood could help in the early diagnosis of AD","volume":"2012","author":"Pesini","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.nbd.2024.106459_bb0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.nbd.2024.106459_bb0180","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/jnnp.2005.085332","article-title":"Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer\u2019s Disease","volume":"77","author":"Portet","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.nbd.2024.106459_bb0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/jpm10040221","article-title":"Fluid candidate biomarkers for Alzheimer\u2019s disease: a precision medicine approach","volume":"10","author":"Prete","year":"2020","journal-title":"J. Personal. Med."},{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0190","first-page":"510","article-title":"\u00ab\u202fplasma amyloid Beta levels are associated with cerebral amyloid and tau deposition\u202f\u00bb. \u00c9dit\u00e9 par Henrik Zetterberg","volume":"11","author":"Risacher","year":"2019","journal-title":"Alzheimer\u2019s Dementia: Diagn. Assess. Disease Monitor."},{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/JAD-2010-101248","article-title":"Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-\u03b2 is an early biomarker for mild cognitive impairment preceding Alzheimer\u2019s disease","volume":"24","author":"Sagare","year":"2011","journal-title":"J. Alzheimer\u2019s Disease: JAD"},{"issue":"9","key":"10.1016\/j.nbd.2024.106459_bb0200","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-Beta by circulating lipoprotein receptors","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.nbd.2024.106459_bb0205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00249-008-0379-8","article-title":"Surfactant-induced conformational transition of amyloid Beta-peptide","volume":"38","author":"Sureshbabu","year":"2009","journal-title":"Eur. Biophys. J.: EBJ"},{"issue":"4","key":"10.1016\/j.nbd.2024.106459_bb0210","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","article-title":"Plasma amyloid-\u03b2 (A\u03b242) correlates with cerebrospinal fluid A\u03b242 in Alzheimer\u2019s disease","volume":"62","author":"Teunissen","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.nbd.2024.106459_bb0215","doi-asserted-by":"crossref","first-page":"fcaa054","DOI":"10.1093\/braincomms\/fcaa054","article-title":"In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer\u2019s disease","volume":"2","author":"Toombs","year":"2020","journal-title":"Brain Commun."},{"issue":"november","key":"10.1016\/j.nbd.2024.106459_bb0220","article-title":"Abnormal amyloid Beta metabolism in systemic abnormalities and Alzheimer\u2019s pathology: insights and therapeutic approaches from periphery","volume":"71","author":"Ullah","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"5","key":"10.1016\/j.nbd.2024.106459_bb0225","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as Prescreener for the earliest A Lzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.nbd.2024.106459_bb0230","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid \u03b2 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.nbd.2024.106459_bb0235","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awaa054","article-title":"Plasma tau, Neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; a population-based cohort study","volume":"143","author":"de Wolf","year":"2020","journal-title":"Brain"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T19:26:07Z","timestamp":1725737167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996124000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":48,"alternative-id":["S0969996124000585"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106459","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The free plasma amyloid A\u03b21\u201342\/A\u03b21\u201340 ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma A\u03b21\u201342\/A\u03b21\u201340 ratio. The BALTAZAR study","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106459"}}